RepliCel Life Sciences Inc., a clinical stage regenerative medicine company focused on the development of autologous cell therapies, today announced the submission of a Clinical Trial Application (CTA) to the German Competent Authority, the Paul-Ehrlich-Institut (PEI), requesting clearance to initiate a Phase 1 clinical trial investigating the use of RCS-01 to treat patients suffering from aged and UV-damaged skin. …read more

Source:: http://www.news-medical.net/news/20150223/RepliCel-submits-CTA-for-RCS-01-study-to-treat-patients-suffering-from-aged-UV-damaged-skin.aspx

      

Related posts:

  1. iPad app aims to help patients suffering from brain injuries, Alzheimer’s
  2. Big data helps treat cancer patients
  3. Louisiana health secretary submits resignation
  4. Interactive e-skin could advance patient monitoring